High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 7, 2014, Pages 1866-1872

  Jeverica, Samo ^a   Golparian, Daniel ^b   Hanzelka, Brian ^c   Fowlie, Andrew J ^c   Matičič, Mojca ^d   Unemo, Magnus ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c VERTEX PHARMACEUTICALS   (United States)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Antimicrobial treatment; Ceftriaxone; Gonorrhoea; N. gonorrhoeae

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BACTERIAL ENZYME; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE INHIBITOR; PROTEIN PARE; SPECTINOMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG; VT 12 008911; ADENOSINE TRIPHOSPHATASE; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; EPSILOMETER TEST; GONORRHEA; IN VITRO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUTATION RATE; MUTATIONAL ANALYSIS; NEISSERIA GONORRHOEAE; NONHUMAN; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST;

ADENOSINE TRIPHOSPHATASES; ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; TOPOISOMERASE INHIBITORS;

EID: 84902491074     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku073     Document Type: Article

References (50)

1. WHO. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections-2008. Geneva: WHO. http://www.who.int/ reproductivehealth/publications/rtis/2008_STI_estimates.pdf (8 March 2014, date last accessed).
2. Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci 2011; 1230: E19-28.
3. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7: 1401-22.
4. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366: 485-7.
5. Stoltey JE, Barry PM. The use of cephalosporins for gonorrhea: an update on the rising problem of resistance. Expert Opin Pharmacother 2012; 13: 1411-20.
6. Lewis DA. The gonococcus fights back: is this time a knock out? Sex Transm Infect 2010; 86: 415-21.
7. Whiley DM, Goire N, Lahra MM et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012, 67: 2059-61.
8. Kirkcaldy RD, Ballard RC, Dowell D. Gonococcal resistance: are cephalosporins next? Curr Infect Dis Rep 2011; 13: 196-204.
9. Deguchi T, Yasuda M, Yokoi S et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003; 9: 35-9.
10. Yokoi S, Deguchi T, Ozawa T et al. Threat to cefixime treatment of gonorrhea. Emerg Infect Dis 2007; 13: 1275-7.
11. Unemo M, Golparian D, Syversen G et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010; 15: pii=19721.
12. Ison CA, Hussey J, Sankar KN et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011; 16: pii=19833.
13. Unemo M, Golparian D, Stary A et al. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 2011; 16: pii=19998.
14. Allen VG, Mitterni L, Seah C et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309: 163-70.
15. Unemo M, Golparian D, Nicholas R et al. High-level cefixime-and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56: 1273-80.
16. Lewis DA, Sriruttan C, Müller EE et al. Phenotypic and genetic characterization of the first two cases of extended-spectrumcephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013; 68: 1267-70.
17. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011; 16: pii=19792.
18. Unemo M, Golparian D, Potočnik M et al. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 2012; 17: pii=20200.
19. Tapsall J, Read P, Carmody C et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009; 58: 683-7.
20. Ohnishi M, Golparian D, Shimuta K et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55: 3538-45.
21. Chen YM, Stevens K, Tideman R et al. Failure of 500 mgof ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013; 68: 1445-7.
22. Tapsall JW, Ndowa F, Lewis DA et al. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7: 821-34.
23. Cámara J, Serra J, Ayats J et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012; 67: 1858-60.
24. WHO, Department of Reproductive Health and Research. Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae. Geneva: WHO, 2012. http://www.who.int/ reproductivehealth/publications/rtis/9789241503501 (8 March 2014, date last accessed).
25. European Centre for Disease Prevention and Control (ECDC). Response Plan to Control and Manage the Threat of Multidrug-resistant Gonorrhoea in Europe. Stockholm: ECDC, 2012. http://www.ecdc.europa.eu/en/ publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan. pdf (8 March 2014, date last accessed).
26. CDC. Cephalosporin-resistant Neisseria gonorrhoeae Public Health Response Plan. 2012. http://www.cdc.gov/std/treatment/ceph-r-response planjuly30-2012.pdf (8 March 2014, date last accessed).
27. Ndowa F, Lusti-Narasimhan M, Unemo M. The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sex Transm Infect 2012; 88: 317-8.
28. Unemo M, Bignell C. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013; 24: 85-92.
29. CDC. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61: 590-4.
30. Brown LB, Krysiak R, Kamanga G et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010; 37: 169-72.
31. Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012; 88: 6-8.
32. Chisholm SA, Quaye N, Cole MJ et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother 2011; 66: 592-5.
33. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect 2012; 88: 589-94.
34. Ison CA, Deal C, Unemo M. Current and future treatment options for gonorrhoea. Sex Transm Infect 2013; 89 Suppl 4: iv52-6.
35. Unemo M, Golparian D, Limnios A et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrob Agents Chemother 2012; 56: 3603-9.
36. Golparian D, Fernandes P, Ohnishi M et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012; 56: 2739-42.
37. Hook E III, Oldach D, Jamieson B et al. A phase II study to evaluate the efficacy and safety of single dose solithromycin (CEM-101) for the treatment of patients with uncomplicated urogenital gonorrhoea. In: Abstracts of the Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, 2013. Abstract O274, p. 44. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
38. Bates AD, Maxwell A. The role of ATP in the reactions of type II DNA topoisomerases. Biochem Soc Trans 2010; 38: 438-42.
39. Pommier Y, Leo E, Zhang H et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17: 421-33.
40. Mayer C, Janin YL. Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. Chem Rev 2014; 114: 2313-42.
41. Charifson PS, Grillot A-L, Grossman TH et al. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 2008; 51: 5243-63.
42. Mani N, Gross CH, Parsons JD et al. In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob Agents Chemother 2006; 50: 1228-37.
43. Grossman TH, Bartels DJ, Mullin S et al. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 2007; 51: 657-66.
44. Unemo M, Fasth O, Fredlund H et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009; 63: 1142-51.
45. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
46. Takei M, Yamaguchi Y, Fukuda H et al. Cultivation of Neisseria gonorrhoeae in liquid media and determination of its in vitro susceptibilities to quinolones. J Clin Microbiol 2005; 43: 4321-7.
47. Moody J, Knapp C. Time-kill assay for determining synergy. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology Press, 2004; 5.10.31-6.
48. National Committee for Clinical Laboratory Standards. Methodology for the Serum Bactericidal Test: Approved Guideline M21-A. NCCLS, Wayne, PA, USA, 1999.
49. National Committee for Clinical Laboratory Standards. Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A. NCCLS, Wayne, PA, USA, 1999.
50. Garcia LS, Isenberg HD. Clinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology Press, 2010.